I agree, it is also dilutive if you don’t participate making the opportunity cost greater.
whilst can’t say it’s in the bag all things are looking very positive.
could be some good news flow this quarter:
- RC220 tox studies
- Oppy conversion completed
- AML Investigator / trial acceptance
- New appointments
I am sure Race have been using their time wisely. Just staple the Tox studies to AML and cardio protect /
FTO basket trial and send into the FDA.
Easy!
Ann: Quarterly Activity Report & Appendix 4C, page-38
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
0.010(0.50%) |
Mkt cap ! $343.9M | |||
| Open | High | Low | Value | Volume |
| $2.04 | $2.09 | $1.92 | $768.4K | 380.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 484 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 3251 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |